[DOI] [PubMed] [Google Scholar] 26.Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, et al
Its Metabolic Daily that seems to fall short, as it contains all five species in amounts that cant possibly meet the lowest effective clinical doses
Evidence Summary: What the Data Suggest Several phase 2 and observational studies highlight the hepatic benefits of GLP1based treatment: Reduced liver fat: Repeated findings in imaging-based studies support this effect Lower liver enzymes: Consistent reductions in ALT/AST levels Fibrosis improvement: Promising trends in noninvasive markers, though further trials are needed While the strongest evidence comes from patients with obesity or type 2 diabetes, benefits in leaner, metabolically abnormal patients are increasingly documented, suggesting broader utility
As we age, this scaffolding weakens, leading to sagging and wrinkles